Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases From a Small Bowel Adenocarcinoma: Multi-Institutional Experience - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Annals of Surgical Oncology Année : 2018

Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases From a Small Bowel Adenocarcinoma: Multi-Institutional Experience

Yang Liu
  • Fonction : Auteur
Yutaka Yonemura
  • Fonction : Auteur
Edward Levine
  • Fonction : Auteur
David Morris
  • Fonction : Auteur
Paul H. Sugarbaker
  • Fonction : Auteur
Jean Tuech
  • Fonction : Auteur
Peter Cashin
  • Fonction : Auteur
John Spiliotis
  • Fonction : Auteur
Ignace de Hingh
  • Fonction : Auteur
Wim Ceelen
  • Fonction : Auteur
Joel Baumgartner
  • Fonction : Auteur
Pompiliu Piso
  • Fonction : Auteur
Kanji Katayama
  • Fonction : Auteur
Marcello Deraco
  • Fonction : Auteur
Shigeki Kusamura
  • Fonction : Auteur
Marc Pocard
Sachio Fushita
  • Fonction : Auteur
Big-Renape Group
  • Fonction : Auteur

Résumé

BACKGROUND: The multi-institutional registry in this study evaluated the outcome after cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal metastases (PM) from small bowel adenocarcinoma (SBA). METHODS: A multi-institutional data registry including 152 patients with PM from SBA was established. The primary end point was overall survival (OS) after CRS plus HIPEC. RESULTS: Between 1989 and 2016, 152 patients from 21 institutions received a treatment of CRS plus HIPEC. The median follow-up period was 20 months (range 1-100 months). Of the 152 patients, 70 (46.1%) were women with a median age of 54 years. The median peritoneal cancer index (PCI) was 10 (mean 12; range 1-33). Completeness of cytoreduction (CCR) 0 or 1 was achieved for 134 patients (88.2%). After CRS and HIPEC, the median OS was 32 months (range 1-100 months), with survival rates of 83.2% at 1 year, 46.4% at 3 years, and 30.8% at 5 years. The median disease-free survival after CCR 0/1 was 14 months (range 1-100 months). The treatment-related mortality rate was 2%, and 29 patients (19.1%) experienced grades 3 or 4 operative complications. The period between detection of PM and CRS plus HIPEC was 6 months or less (P = 0.008), and multivariate analysis identified absence of lymph node metastasis (P = 0.037), well-differentiated tumor (P = 0.028), and PCI of 15 or lower (P = 0.003) as independently associated with improved OS. CONCLUSION: The combined treatment strategy of CRS plus HIPEC achieved prolonged survival for selected patients who had PM from SBA with acceptable morbidity and mortality.

Dates et versions

hal-02290071 , version 1 (17-09-2019)

Identifiants

Citer

Yang Liu, Yutaka Yonemura, Edward Levine, Olivier Glehen, Diane Goere, et al.. Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases From a Small Bowel Adenocarcinoma: Multi-Institutional Experience. Annals of Surgical Oncology, 2018, 25 (5), pp.1184-1192. ⟨10.1245/s10434-018-6369-x⟩. ⟨hal-02290071⟩
99 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More